Assoc Professor, HemOnc (Emory) Leukemia

Dr. Panoskaltsis is a clinician-scientist with a niche interest in translational interdisciplinary research focused on the study of normal and abnormal blood formation. She completed her Medical Degree at the University of Toronto, Canada followed by a Residency in Internal Medicine and back-to-back Fellowships in Hematology and Bone Marrow Transplantation at the University of Rochester, NY, USA. She thereafter completed a PhD in Immunology at Imperial College London, UK where she also co-founded the BioMedical Systems Engineering Laboratory for interdisciplinary and translational research (at Imperial College London, 2004) with Dr Mantalaris, now located jointly in the Wallace H. Coulter Department of Biomedical Engineering at The Georgia Institute of Technology and Winship Cancer Institute, Emory University.

Dr. Panoskaltsis’ subspecialty is in Acute Myeloid Leukemia (AML), specifically in (1) the immune biology and pathogenesis of the disorder, (2) the development of innovative strategies to treat/prevent disease using 3D ex vivo culture models and, (3) in creating novel immuno-chemotherapeutic precision treatments for AML using in silico mathematical modelling. She has over 25 years’ experience in Phase I-Phase IV trials in Hematologic Malignancies, with particular emphasis in AML and myeloid neoplasms. In 2006, due to her expertise in Hemato-Oncology, Immunology and clinical trials, she handled the aftermath of the serious adverse event which occurred in London after 6 healthy volunteers were administered TGN1412, an anti-CD28 super-agonist antibody, and caused a near-fatal cytokine storm. The successful handling of the event resulted in changes in the conduct of first-in-man trials internationally for novel higher-risk therapeutics, and also sowed the seeds in her own research of creating ways in which to improve efficacy and reduce toxicity in AML treatment via mathematical modelling. She co-founded SANICKA, Inc in 2021 to address this unmet need.